Search hospitals
>
Nova Scotia
>
HALIFAX
IWK Health Centre
Claim this profile
HALIFAX, Nova Scotia B3K 6R8
Global Leader in Leukemia
Global Leader in Brain Tumor
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Cancer
Conducts research for Neuroblastoma
311 reported clinical trials
11 medical researchers
Summary
IWK Health Centre is a medical facility located in HALIFAX, Nova Scotia. This center is recognized for care of Leukemia, Brain Tumor, Acute Lymphoblastic Leukemia, Cancer, Neuroblastoma and other specialties. IWK Health Centre is involved with conducting 311 clinical trials across 502 conditions. There are 11 research doctors associated with this hospital, such as Craig Erker, Jennifer Foster, MD, Adam Huber, MD, and Anthony Otley.
Area of expertise
Leukemia
IWK Health Centre has run 37 trials for Leukemia. Some of their research focus areas include:
Brain Tumor
IWK Health Centre has run 33 trials for Brain Tumor. Some of their research focus areas include:
Top PIs
Craig Erker
IWK Health Centre
5 years of reported clinical research
Jennifer Foster, MD
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
3 years of reported clinical research
Adam Huber, MD
IWK Health Center
7 years of reported clinical research
Anthony Otley
IWK Health Centre
2 years of reported clinical research
Clinical Trials running at IWK Health Centre
Brain Tumor
Testicular cancer
Wilms Tumor
Crohn's Disease
Neuroblastoma
Acute Lymphoblastic Leukemia
Burkitt Lymphoma
Ovarian Carcinoma
Ovarian Tumors
Testicular Carcinoma
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting
2 awards
Phase 3
Chemotherapy + Radiation Therapy
for Brain Cancer
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.
Recruiting
1 award
Phase 2
Lower Radiotherapy Dose
for Brain Tumors
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.
Recruiting
1 award
Phase 2
10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at IWK Health Centre?
IWK Health Centre is a medical facility located in HALIFAX, Nova Scotia. This center is recognized for care of Leukemia, Brain Tumor, Acute Lymphoblastic Leukemia, Cancer, Neuroblastoma and other specialties. IWK Health Centre is involved with conducting 311 clinical trials across 502 conditions. There are 11 research doctors associated with this hospital, such as Craig Erker, Jennifer Foster, MD, Adam Huber, MD, and Anthony Otley.
Where is IWK Health Centre located?
The IWK Health Centre is located at 5980 University Ave, Halifax, NS B3K 0B4, Canada.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at IWK Health Centre, please visit their official website and use the "Contact Us" form for detailed information. For bill payments and related inquiries, contact Nova Scotia Health through their centralized contact options.
What insurance does IWK Health Centre accept?
The IWK Health Centre accepts various insurance plans, including those from Nova Scotia's Health Insurance Programs and other provincial health plans for residents of Canadian provinces. These programs cover a wide range of services such as hospital visits and stays, doctor visits, medically necessary dental and optometric services, and more. Employees of the IWK Health Centre have access to mandatory benefits like basic life insurance, long-term disability, and pension through NSHEPP, with optional benefits available.
What awards or recognition has IWK Health Centre received?
The IWK Health Centre in Halifax, Nova Scotia, is primarily funded by government sources for its operational costs. It also benefits from donations made to the IWK Foundation, which support the purchase of specialized equipment and research initiatives. In 2022, the IWK Foundation contributed $5,427 in cash donations, with an additional $1,704 receivable.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.